Ambenonium
Mytelase (ambenonium) is a small molecule pharmaceutical. Ambenonium was first approved as Mytelase on 1982-01-01. It is used to treat myasthenia gravis in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ambenonium chloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MYTELASE | Sanofi | N-010155 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| myasthenia gravis | EFO_0004991 | D009157 | G70.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
76 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 4 | 4 | 5 | 3 | 15 |
| Traumatic brain injuries | D000070642 | S06 | 1 | 1 | 1 | 3 | 4 | 9 | |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | 4 | 1 | — | 5 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | 2 | 1 | — | 5 |
| Cocaine-related disorders | D019970 | F14 | 1 | 3 | — | 1 | — | 5 | |
| Psychotic disorders | D011618 | F20.81 | 1 | — | 1 | 1 | — | 3 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 1 | — | 1 | — | 3 |
| Postoperative cognitive complications | D000079690 | — | — | — | 1 | 1 | 2 | ||
| Chorea | D002819 | EFO_0004152 | G25.5 | — | 1 | — | 1 | — | 2 |
| Cerebral palsy | D002547 | G80 | — | — | — | 1 | — | 1 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 1 | 3 | — | 2 | 6 | |
| Dyskinesias | D020820 | G24 | — | 1 | 3 | — | — | 3 | |
| Recurrence | D012008 | — | 1 | 2 | — | — | 2 | ||
| Hepatitis c | D006526 | B19.2 | — | 1 | 2 | — | — | 2 | |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | 1 | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 1 | — | — | 1 |
| Sars-cov-2 | D000086402 | — | — | 1 | — | — | 1 | ||
| Spinal curvatures | D013121 | M43.9 | — | 1 | 1 | — | — | 1 | |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coma | D003128 | HP_0001259 | R40.2 | — | 1 | — | — | 2 | 3 |
| Consciousness disorders | D003244 | 1 | 1 | — | — | — | 2 | ||
| Human influenza | D007251 | EFO_0007328 | J11.1 | — | 2 | — | — | — | 2 |
| Neoplasms | D009369 | C80 | — | 1 | — | — | 1 | 2 | |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Intratracheal intubation | D007442 | — | 1 | — | — | — | 1 | ||
| Hypoxia | D000860 | R09.02 | — | 1 | — | — | — | 1 | |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | 1 | — | — | — | 1 |
| Drug-induced dyskinesia | D004409 | EFO_1000904 | — | 1 | — | — | — | 1 | |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aggression | D000374 | EFO_0003015 | — | — | — | — | 2 | 2 | |
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | 1 | 1 | |
| Persistent vegetative state | D018458 | R40.3 | — | — | — | — | 1 | 1 | |
| Brain injuries | D001930 | S06.9 | — | — | — | — | 1 | 1 | |
| Irritable mood | D007508 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | AMBENONIUM |
| INN | ambenonium chloride |
| Description | Ambenonium is a symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives; quaternary ammonium derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl |
Identifiers
| PDB | — |
| CAS-ID | 7648-98-8 |
| RxCUI | 623 |
| ChEMBL ID | CHEMBL1652 |
| ChEBI ID | 2627 |
| PubChem CID | 2131 |
| DrugBank | DB01122 |
| UNII ID | 51FOB87G3I (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 150 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,549 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more